{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:04:11Z","timestamp":1787241851342,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Nauki i Szkolnictwa Wy\u017cszego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.ejphar.2011.10.030","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T12:52:48Z","timestamp":1319806368000},"page":"20-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model"],"prefix":"10.1016","volume":"674","author":[{"given":"Karolina M.","family":"Stepien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Tomaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarogniew J.","family":"Luszczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislaw J.","family":"Czuczwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2011.10.030_bb0005","doi-asserted-by":"crossref","first-page":"29A","DOI":"10.1016\/S0002-9149(05)80012-8","article-title":"Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus","volume":"76","author":"Appel","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0200","doi-asserted-by":"crossref","first-page":"III-50","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000134913","article-title":"Une nouvelle m\u00e9thode simple pour explorer l'action tranquilisante: Le test de la chemin\u00e9e","volume":"3","author":"Boissier","year":"1960","journal-title":"Med. Exp. (Basel)"},{"key":"10.1016\/j.ejphar.2011.10.030_bb1000","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/j.1471-4159.2004.02980.x","article-title":"Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones","volume":"92","author":"B\u00f6sel","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/j.1528-1157.1997.tb01224.x","article-title":"Commission on European affairs: appropriate standards of epilepsy care across Europe","volume":"38","author":"Brodie","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0025","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eplepsyres.2010.07.021","article-title":"The association between antiepileptic drugs and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy","volume":"91","author":"Candrilli","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0030","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0009-9236(96)90218-0","article-title":"Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastation, an inhibitor of HMG-CoA reductase, in healthy subjects","volume":"60","author":"Cilia","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0035","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0140-6736(04)15946-1","article-title":"Late onset seizures as a predictor of subsequent stroke","volume":"363","author":"Cleary","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0163-7258(99)00045-5","article-title":"New insight into the pharmacodynamic and pharmacokinetic properties of statins","volume":"84","author":"Corsini","year":"1999","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0045","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00228-002-0557-z","article-title":"Potential drug\u2013drug interactions in the medication of medical patients at hospital discharge","volume":"58","author":"Egger","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0050","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1161\/01.STR.0000143319.73503.38","article-title":"Effects of statins on endothelium and signalling mechanisms","volume":"35","author":"Endres","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0055","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1212\/WNL.0b013e3181f96253","article-title":"Statin use and risk of epilepsy","volume":"75","author":"Etminan","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0060","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/01.wnl.0000341789.77291.8d","article-title":"Assessment of potential drug interactions in patients with epilepsy. Impact of age and sex","volume":"72","author":"Gidal","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0065","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1161\/STROKEAHA.107.513747","article-title":"Relative effect of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study","volume":"39","author":"Goldstein","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0070","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1592\/phco.26.11.1601","article-title":"Role of p-glycoprotein in statin drug interactions","volume":"26","author":"Holtzman","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0075","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0080","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0085","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2011.10.030_bb1005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.neulet.2008.05.112","article-title":"Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death","volume":"440","author":"Lee","year":"2008","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose\u2013effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0095","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2007.07.008","article-title":"Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice","volume":"574","author":"Luszczki","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0100","first-page":"444","article-title":"A prospective assessment of the effect of phenytoin on the pharmacokinetics of atorvastatin","volume":"49","author":"Miller","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/pgmj.75.884.359","article-title":"Efficacy of statin therapy: possible effect of phenytoin","volume":"75","author":"Murphy","year":"1998","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1179\/174313208X353686","article-title":"Impact of statins on validation of ICH mortality prediction models","volume":"31","author":"Naval","year":"2009","journal-title":"Neurol. Res."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2165\/00003088-200847070-00003","article-title":"Pharmacokinetic comparison of the potential over-the-conter statins simvastatin, lovastatin, fluvastatin and pravastatin","volume":"47","author":"Neuvonen","year":"2008","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0120","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1089\/0897715041269641","article-title":"The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration","volume":"21","author":"Park","year":"2004","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0130","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/j.1552-4604.1996.tb04242.x","article-title":"Tolerance and pharmacokinetics of single-dose atorvastatin, a potential inhibitor of HMG-CoA reductase, in healthy subjects","volume":"36","author":"Posvar","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0135","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug\u2013drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"Ratz Bravo","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0140","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1023\/A:1018975928974","article-title":"In vitro and in vivo blood brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (MG-CoA) reductase inhibitors","volume":"11","author":"Saheki","year":"1994","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0145","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jps.2600830409","article-title":"A pharmacodynamic approach to the estimate of carbamazepine autoinduction","volume":"84","author":"Scheyer","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0150","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00003088-200140040-00003","article-title":"Clinical pharmacokinetics of fluvastatin","volume":"40","author":"Scripture","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug\u2013drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0160","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3233\/JAD-2010-101179","article-title":"Statins as neuroprotectants: A comparative in vivo study of lipophilicity, blood\u2013brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death","volume":"23","author":"Sierra","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0165","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/187152509789541864","article-title":"Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors","volume":"7","author":"Smaldone","year":"2009","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0170","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2125.2007.02982.x","article-title":"Statins and phenytoin interact\u2014a case history","volume":"65","author":"Tan","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0175","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00228-003-0700-5","article-title":"Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid","volume":"59","author":"Ucar","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0180","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/321864a0","article-title":"Benzodiazepine impairs and beta-carboline enhances performance in learning and memory task","volume":"321","author":"Venault","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0185","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1111\/j.1528-1167.2005.00298.x","article-title":"Brain inflammation in epilepsy: experimental and clinical evidence","volume":"46","author":"Vezzani","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejphar.2011.10.030_bb0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200241050-00003","article-title":"Pharmacokinetic\u2013pharmadynamic drug interactions with HMG-CoA reductase inhibitors","volume":"41","author":"Williams","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2011.10.030_bb0195","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","article-title":"Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"57","author":"Wolozin","year":"2000","journal-title":"Arch. Neurol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911013987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299911013987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:14:46Z","timestamp":1757974486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299911013987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0014299911013987"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.10.030","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2011.10.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2011 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}